Insights
Insights From Our Experts
Articles
BLOG: Moving to More Comprehensive HEOR Data
Posted by
Dr. Richard Stefanacci on September 28, 20219/28/21
Health economics and outcomes research (HEOR) by definition is a discipline that is used to complement traditional clinical development information (i.e., efficacy, safety, quality) to guide patient access decision-makers to specific drugs and services. The foundation of…
Assessing Market Opportunity and Entry Challenges in Mental Health Disorders
Although mental health disorders affect almost 264 million people worldwide, they are often misunderstood and misdiagnosed, and access is poor. The World Health Organization (WHO) reports that 80% of people in low- and middle-income countries receive…
Increasing the Value of Community Health Workers
In developing countries, frontline community health workers (CHWs) extend basic healthcare services to communities. These extensive CHW networks provide services that improve various health indicators. The Philippines has set a goal of one CHW (“Barangay Health…
Getting Treatments to Patients When They Need Them Most: Next Gen Commercialization in Oncology
Commercializing oncology products is extremely complex, but successfully launching new therapies to market is essential for patients and providers in the fight against cancer. In 2020, about 10 million people died from cancer, proving even in…
Novel Antibiotic Opportunity in China
China, with its large population and extensive healthcare system, is the second-highest user of antibiotics in the world. Such widespread use has inevitably led to high levels of antibiotic resistance in the population. When isolated, it…
How Do You Know Your Portfolio Process Is Adding Value?
In 1998, Rob Arnold, Executive Vice President, teamed with some colleagues to publish an article in the Harvard Business Review that highlighted the practical results obtained by applying modern R&D portfolio thinking to SmithKline Beecham’s late-stage…
Measuring the Impact of Coordinated Field and Digital Engagement Through Network Influence: An Omnichannel Case Study
Posted on September 17, 20219/17/21
In today’s competitive global market, pharmaceutical companies can’t afford to waste time or resources on strategies that don’t generate scripts or fit product and patient needs. Without data-informed, fully integrated campaigns, there’s a missed opportunity to…
TOP NEWS: CMS Proposes Repeal on Medicare Coverage of Innovative Technologies Initiative
In a reversal of its upcoming policy to cover breakthrough designated medical devices, the Centers for Medicare and Medicaid Services (CMS) on Monday issued a proposed rule that would completely repeal the Medicare Coverage of Innovative…
Assessing the Feasibility of ITCs
When looking at different healthcare interventions for a disease, there may be limited direct evidence on how the treatments compare with each other in terms of their efficacy, tolerability or another measure of interest. In this…
Simplifying EU Distribution to Maximize Cost Efficiency and Speed to Market for Patients and Manufacturers
Posted by
Franjo Hanzl on September 14, 20219/14/21
COVID-19 ignited a spark of innovation in the healthcare industry, forcing global markets to reconsider drug development and commercialization processes. The European Union (EU), specifically, is taking carefully planned steps into a new phase of pharma…